-transparent.png){kind=logo}
During maintenance treatment with nocturnal ranitidine (150 mg) for 1 year, 38% of duodenal ulcers relapsed. Twenty-one patients whose ulcers remained healed after maintenance treatment for 1 year continued to receive ranitidine (150 mg at night) for a further year, while 26 patients with healed ulcers received placebo in a randomized double-blind study. The rate of recurrence of duodenal ulcers during the 2nd year of follow-up study was 18% in ranitidine-treated individuals and 87% in those receiving placebo. The ulcer recurrences of patients receiving ranitidine tended to be asymptomatic and were clinically mild in the rest. Recurrences in patients receiving placebo were usually symptomatic and significantly more likely to be associated with bleeding. We conclude that ulcers that remain healed after 1 year's maintenance treatment with ranitidine tend to remain healed if maintenance treatment is continued. Moreover, this type of continuous treatment of duodenal ulcer is clinically safer than no treatment of the ulcer disease.
E J Boyd, and
J A Wilson, and
K G Wormsley
October 1986,
Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology,
E J Boyd, and
J A Wilson, and
K G Wormsley
July 1987,
Medicina clinica,
E J Boyd, and
J A Wilson, and
K G Wormsley
November 1984,
Scandinavian journal of gastroenterology,
E J Boyd, and
J A Wilson, and
K G Wormsley
January 1983,
International journal of tissue reactions,
E J Boyd, and
J A Wilson, and
K G Wormsley
January 1992,
Gastroenterologie clinique et biologique,
E J Boyd, and
J A Wilson, and
K G Wormsley
January 1990,
Vutreshni bolesti,
E J Boyd, and
J A Wilson, and
K G Wormsley
October 1992,
Alimentary pharmacology & therapeutics,
E J Boyd, and
J A Wilson, and
K G Wormsley
August 1986,
Zhonghua nei ke za zhi,
E J Boyd, and
J A Wilson, and
K G Wormsley
January 1987,
Zhonghua nei ke za zhi,
E J Boyd, and
J A Wilson, and
K G Wormsley
January 1984,
Vutreshni bolesti,
